Form 8-K

8-K — Armata Pharmaceuticals, Inc.

Accession: 0001104659-26-084861

Filed: 2026-07-20

Period: 2026-07-20

CIK: 0000921114

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2620782d2_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2620782d2_ex99-1.htm)

GRAPHIC (tm2620782d2_ex99-1img001.jpg)

GRAPHIC (tm2620782d2_ex99-1img002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620782d2_8k.htm · Sequence: 1

false

0000921114

2026-07-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND

EXCHANGE COMMISSION

Washington, DC

20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

July 20, 2026

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in

its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction

of incorporation or

organization)

(Commission File Number)

(IRS Employer Identification No.)

5005 McConnell Avenue

Los Angeles, California

90066

(Address of principal executive offices)

(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§

230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the

registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of

the Act:

Title

of Each Class

Trading

Symbol(s)

Name

of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 7.01

Regulation FD Disclosure.

On July 20, 2026, Armata Pharmaceuticals, Inc.

(the “Company”) issued a press release announcing significant clinical, regulatory,

manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococcus

aureus (“S. aureus”) multi-phage product candidate, toward a planned Phase 3 superiority study for adjunct treatment

of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin-resistant S. aureus

(“MRSA”).

The press release further discussed a $2.5 million

award announced on June 23, 2026 from the U.S. Department of Defense, which is a continuation of a previously announced award and brings

total funding received to date under that award to $28.7 million. These additional $2.5 million funds are intended to support activities

related to the Company’s continued preparation and readiness for its planned Phase 3 clinical study. The Company is in close communication

with its partners at the DoD regarding potential new support, including for the execution of the planned Phase 3 clinical study. Separate

from this existing DoD award, or any potential new DoD award, the Company also continues to pursue and evaluate other funding pathways

to support execution of the planned Phase 3 clinical study.

The press release further

provided a corporate update, including the promotion of David House to Chief Financial Officer.

The full text of the press release issued in connection

with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and the attached Exhibit 99.1 is

being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as

amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall

not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated July 20, 2026.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned hereunto duly authorized.

Date: July 20, 2026

Armata Pharmaceuticals, Inc.

By:

/s/ David House

Name:

David House

Title:

Chief Financial Officer

- 3 -

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2620782d2_ex99-1.htm · Sequence: 2

Exhibit 99.1

Armata Pharmaceuticals Achieves Key Progress

Across Clinical, Regulatory and Manufacturing Activities

Supporting Planned Phase 3 Initiation of AP-SA02

FDA submissions address all feedback on clinical,

CMC, and regulatory topics from the End-of-Phase 2 meeting

Four AP-SA02 engineering runs completed; clinical

trial material production is the next planned manufacturing step

Phase 3 superiority study remains on track to

initiate in the second half of 2026

LOS ANGELES, Calif., July 20, 2026 - Armata Pharmaceuticals, Inc.

(NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on

the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and

difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing and operational progress

supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococcus

aureus (“S. aureus”) multi-phage product candidate, toward a planned Phase 3 superiority study for

adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or

methicillin-resistant S. aureus (“MRSA”).

Recent milestones include submission of the complete Phase 3 protocol

and comprehensive responses to all comments received from the U.S. Food and Drug Administration (“FDA”) following the Company’s

End-of-Phase 2 (EOP2) meeting, and completion of key manufacturing activities supporting Phase 3 readiness. Collectively, these milestones

support the Company’s planned initiation of its pivotal Phase 3 superiority study in the second half of 2026, designed to support

a future Biologics License Application (“BLA”) for AP-SA02.

Recent Regulatory and Operational Progress

· Submitted the complete Phase 3 superiority protocol to the FDA for AP-SA02, incorporating all comments received in the End-of-Phase

2 (“EOP2”) meeting written response.

· Submitted complete responses to all FDA comments on clinical, Chemistry, Manufacturing, and Controls, (“CMC”) and regulatory

topics raised in the EOP2 meeting written response.

· Completed four engineering runs of AP-SA02 at the Company’s in-house cGMP manufacturing facility in Los Angeles, CA. Production

of clinical trial material to support the planned Phase 3 clinical study is the next planned manufacturing step.

Department of Defense (DoD) Award

The $2.5 million announced on June 23, 2026 is a continuation of the

previously announced award from the U.S. Department of Defense (“DoD”) i bringing total funding received to date

under this award to $28.7 million. These additional $2.5 million funds are intended to support activities related to Armata’s continued

preparation and readiness for its planned Phase 3 clinical study. The Company is in close communication with its partners at the DoD regarding

potential new support, including for the execution of the planned Phase 3 clinical study.

Separate from the existing or any new DoD award, the Company continues

to pursue and evaluate other funding pathways to support the execution of the planned Phase 3 clinical study.

“Advancing AP-SA02 into a Phase 3 superiority study in complicated

S. aureus bacteremia remains our top priority,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “These submissions

move us closer to that goal, and we are focused on initiating a rigorously designed and operationally efficient study to support a future

Biologics License Application and potential registration.”

Executive Leadership Update

Armata also announced the promotion of David House to Chief Financial

Officer. Mr. House has served as the Company’s Senior Vice President, Finance and Principal Financial Officer since August 2024.

The appointment ensures Armata has the right financial leadership in place to execute on its strategy and advance its clinical programs

through late-stage development.

Department of Defense (DoD) award received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical

Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter

Medical Research Program.

About AP-SA02

Armata

is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia

caused by methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). AP-SA02 has received Qualified

Infectious Disease Product (QIDP), and Fast Track designations from the FDA. The diSArm study (NCT05184764) was a Phase

1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability,

and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo)

for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were

highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into

a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.

About Armata Pharmaceuticals, Inc.

Armata is a late clinical-stage biotechnology company focused on the

development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat

bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural

and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens.

Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific

current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.

Forward Looking Statements

This

communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These

statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties

and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results,

performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms

such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”

“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”

“would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s

beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are

subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata’s

planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated

milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics;

ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete

preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products

on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs

for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk

Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”),

including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release

publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations

with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:

Pierre Kyme

ir@armatapharma.com

310-665-2928

Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569

GRAPHIC

Filename: tm2620782d2_ex99-1img001.jpg · Sequence: 6

Binary file (10045 bytes)

Download tm2620782d2_ex99-1img001.jpg

GRAPHIC

Filename: tm2620782d2_ex99-1img002.jpg · Sequence: 7

Binary file (2015 bytes)

Download tm2620782d2_ex99-1img002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jul. 20, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 20, 2026

Entity File Number

001-37544

Entity Registrant Name

ARMATA PHARMACEUTICALS, INC.

Entity Central Index Key

0000921114

Entity Tax Identification Number

91-1549568

Entity Incorporation, State or Country Code

Entity Address, Address Line One

5005 McConnell Avenue

Entity Address, City or Town

Los Angeles

Entity Address, State or Province

Entity Address, Postal Zip Code

90066

City Area Code

310

Local Phone Number

655-2928

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

ARMP

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration